1. Pink Sheet

J&J Oklahoma Judgement May Set Benchmark For Massive Opioid Resolution

 
• By Brenda Sandburg

Judge orders J&J to pay $572m for one-year abatement plan; the state had proposed $12bn over 20-year period. J&J's gamble on a trial has so far not succeeded, since it is now facing more than twice the payout that Purdue agreed to in a settlement.

Judge or auction gavel on Oklahoma US of America waving flag background. 3d illustration - Illustration

Johnson & Johnson lost a gamble in going to trial over Oklahoma's claims it helped create the opioid crisis as a district court judge issued a $572m judgement against the company to fund a one-year abatement plan. The sum is $300m more than Purdue agreed to pay in its settlement with the state but a fraction of the $12.8bn the state estimated it would cost to ameliorate the crisis over a 20-year period.

Oklahoma alleged that J&J and its Janssen Pharmaceuticals Inc. unit engaged in a false, misleading, and deceptive marketing campaign...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

EU Health Chief Declares There Is No Better Alternative Than TEVs to Spark Antibiotic Innovation

 
• By Francesca Bruce

Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.

EU Fines Alchem Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 
• By Eliza Slawther

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.